Key Details
Price
$0.45Annual ROE
-55.95%Beta
1.01Events Calendar
Next earnings date:
Mar 21, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
Mar 21, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Turnstone Biologics Corp. (TSBX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Announced positive initial data from Phase 1 trial of TIDAL-01 in metastatic colorectal cancer including a complete response in one of the four patients reported Cash position expected to fund operations into 3Q 2025 SAN DIEGO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today reported financial results for the second quarter ended June 30, 2024, and provided recent business highlights. “We have continued to bolster our position by making advances across our pipeline and corporate operations in the second quarter of 2024.
On July 25, 2023, FMR LLC (Trades, Portfolio), a renowned investment firm, made a significant move in the biotechnology sector by acquiring a substantial stake in Turnstone Biologics Corp ( TSBX , Financial). This article provides an in-depth analysis of the transaction, profiles of both FMR LLC (Trades, Portfolio) and Turnstone Biologics Corp, and the potential implications of this acquisition on the market.
Turnstone Biologics Corp. TSBX, is headed for its public debut Friday, as the San Diego-based biotechnology company focused on treating tumors raised $80 million through an upsized initial public offering. The company said it sold 6.67 million shares in the IPO, up from a previously expected offering of 5.80 million shares.
Turnstone Biologics Corp. has filed proposed terms for a $75.4 million IPO. The firm is developing drug treatment candidates for solid tumors and other cancer conditions. Turnstone Biologics' major partners have terminated their collaboration agreements, so I'm cautious about the firm's prospects.
Turnstone Biologics TSBX, , a clinical-stage biotech that specializes in treatments for solid tumors, set terms for its initial public offering on Monday with plans to offer 5.8 million shares priced at $12 to $14 each. The company would raise $81.2 million at the top of that range at a valuation of $298 million.
FAQ
- What is the ticker symbol for Turnstone Biologics?
- Does Turnstone Biologics pay dividends?
- What sector is Turnstone Biologics in?
- What industry is Turnstone Biologics in?
- What country is Turnstone Biologics based in?
- When did Turnstone Biologics go public?
- Is Turnstone Biologics in the S&P 500?
- Is Turnstone Biologics in the NASDAQ 100?
- Is Turnstone Biologics in the Dow Jones?
- When was Turnstone Biologics's last earnings report?
- When does Turnstone Biologics report earnings?
- Should I buy Turnstone Biologics stock now?